In this review:
- Revised McDonald criteria 2023
- Does high-dose simvastatin slow progression of disability in SPMS?
- Efficacy of tolebrutinib in non-relapsing SPMS: the HERCULES trial
- New clinical subtypes of MS identified
- Unveiling specialists’ views on MS prognostication
- Misdiagnosis of MS in an adult neurogenetics clinic
- Safety and efficacy of frexalimab in RMS
- Short-term B cell depletion results in long-term freedom from disease activity in some RMS patients
- Impact of alternate-day fingolimod tapering on rebound disease activity in MS
- B cell tailored dosing vs standard interval dosing of ocrelizumab
- High efficacy treatment discontinuation vs continuation in patients older than 50 with stable MS
Please login below to download this issue (PDF)